BioCentury
ARTICLE | Emerging Company Profile

With $70M A round, Takeda deal, 5AM’s Ensoma aims for accessible cell and gene therapies via empty adenoviral vectors

Emerging Company Profile: Ensoma is taking on ex vivo HSC therapies

February 12, 2021 3:04 AM UTC


Access this Article

BCIQ Company Profiles

Takeda Pharmaceutical Co. Ltd.